| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| BYAHPark Ha Biological Technology Co., Ltd. Ordinary Shares | 2.34M | 0.16 | 8.63 | -3.14% | 20.09% | 38% | 37.35% | 0.05 |
| RGSRegis Corporation | 61.49M | 24.79 | 0.57 | 3.52% | 53.46% | 63.58% | 20.25% | 1.89 |
| Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | |
|---|---|---|---|---|
| Sales/Revenue | 931.04K | 1.92M | 2.46M | 2.38M |
| Revenue Growth % | - | 1.06% | 0.28% | -0.03% |
| Cost of Goods Sold | 311.16K | 509.16K | 310.99K | 195.34K |
| COGS % of Revenue | 0.33% | 0.27% | 0.13% | 0.08% |
| Gross Profit | 619.87K | 1.41M | 2.15M | 2.19M |
| Gross Margin % | 0.67% | 0.73% | 0.87% | 0.92% |
| Gross Profit Growth % | - | 1.28% | 0.52% | 0.02% |
| Operating Expenses | 1.12M | 1.21M | 967.56K | 1.39M |
| OpEx % of Revenue | 1.2% | 0.63% | 0.39% | 0.58% |
| Selling, General & Admin | 1.12M | 1.15M | 784.57K | 1.18M |
| SG&A % of Revenue | 1.2% | 0.6% | 0.32% | 0.49% |
| Research & Development | 0 | 60.67K | 30.88K | 36.71K |
| R&D % of Revenue | - | 0.03% | 0.01% | 0.02% |
| Other Operating Expenses | 0 | 6.44K | 152.11K | 179.9K |
| Operating Income | -500.98K | 197.02K | 1.18M | 793.71K |
| Operating Margin % | -0.54% | 0.1% | 0.48% | 0.33% |
| Operating Income Growth % | - | 1.39% | 4.99% | -0.33% |
| EBITDA | -461.97K | 227.51K | 1.2M | 816.4K |
| EBITDA Margin % | -0.5% | 0.12% | 0.49% | 0.34% |
| EBITDA Growth % | - | 1.49% | 4.28% | -0.32% |
| D&A (Non-Cash Add-back) | 39.01K | 30.49K | 20.06K | 22.69K |
| EBIT | -483.76K | 190.2K | 1.18M | 793.71K |
| Net Interest Income | -1.03K | 69 | 1.59K | 783 |
| Interest Income | 167 | 263 | 1.59K | 783 |
| Interest Expense | 1.19K | 194 | 0 | 0 |
| Other Income/Expense | 16.02K | -7.01K | 1.01K | -293 |
| Pretax Income | -484.96K | 190.01K | 1.18M | 793.42K |
| Pretax Margin % | -0.52% | 0.1% | 0.48% | 0.33% |
| Income Tax | 0 | -1.29K | 329.53K | 314.86K |
| Effective Tax Rate % | 1% | 1.01% | 0.72% | 0.6% |
| Net Income | -484.96K | 191.3K | 852.04K | 478.56K |
| Net Margin % | -0.52% | 0.1% | 0.35% | 0.2% |
| Net Income Growth % | - | 1.39% | 3.45% | -0.44% |
| Net Income (Continuing) | -484.96K | 191.3K | 852.04K | 478.56K |
| Discontinued Operations | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.02 | 0.01 | 0.03 | 0.02 |
| EPS Growth % | - | 1.39% | - | -0.44% |
| EPS (Basic) | -0.02 | 0.01 | 0.03 | 0.02 |
| Diluted Shares Outstanding | 26.2M | 26.2M | 26.2M | 26.2M |
| Basic Shares Outstanding | 26.2M | 26.2M | 26.2M | 26.2M |
| Dividend Payout Ratio | - | - | - | - |
| Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | |
|---|---|---|---|---|
| Total Current Assets | 473.59K | 2.26M | 2.18M | 2.84M |
| Cash & Short-Term Investments | 72.69K | 574.71K | 1.03M | 547.5K |
| Cash Only | 72.69K | 574.71K | 1.03M | 547.5K |
| Short-Term Investments | 0 | 0 | 0 | 0 |
| Accounts Receivable | 79.71K | 1.53M | 710.78K | 1.11M |
| Days Sales Outstanding | 31.25 | 290.13 | 105.5 | 170.05 |
| Inventory | 316.51K | 94.17K | 95.87K | 71.49K |
| Days Inventory Outstanding | 371.28 | 67.51 | 112.52 | 133.58 |
| Other Current Assets | 0 | 59.52K | 233.48K | 1.09M |
| Total Non-Current Assets | 120.62K | 254.09K | 88.72K | 239.04K |
| Property, Plant & Equipment | 106.76K | 62.82K | 70.44K | 174.7K |
| Fixed Asset Turnover | 8.72x | 30.55x | 34.91x | 13.63x |
| Goodwill | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 9.35K | 8.4K | 7.62K |
| Long-Term Investments | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 13.86K | 181.92K | 9.88K | 407 |
| Total Assets | 594.22K | 2.52M | 2.26M | 3.08M |
| Asset Turnover | 1.57x | 0.76x | 1.09x | 0.77x |
| Asset Growth % | - | 3.24% | -0.1% | 0.36% |
| Total Current Liabilities | 1.16M | 2.37M | 1.24M | 1.52M |
| Accounts Payable | 89.34K | 129.72K | 197.16K | 24.07K |
| Days Payables Outstanding | 104.8 | 92.99 | 231.4 | 44.97 |
| Short-Term Debt | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 164.81K | 1000K | 250.55K | 325.92K |
| Other Current Liabilities | 0 | 0 | 0 | 0 |
| Current Ratio | 0.41x | 0.96x | 1.75x | 1.87x |
| Quick Ratio | 0.14x | 0.92x | 1.67x | 1.82x |
| Cash Conversion Cycle | 297.72 | 264.64 | -13.38 | 258.65 |
| Total Non-Current Liabilities | 15.86K | 0 | 9.49K | 52.74K |
| Long-Term Debt | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 15.86K | 0 | 9.49K | 52.74K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.17M | 2.37M | 1.25M | 1.58M |
| Total Debt | 35.2K | 26.19K | 31.46K | 70.32K |
| Net Debt | -37.48K | -548.52K | -1M | -477.18K |
| Debt / Equity | - | 0.17x | 0.03x | 0.05x |
| Debt / EBITDA | - | 0.12x | 0.03x | 0.09x |
| Net Debt / EBITDA | - | -2.41x | -0.83x | -0.58x |
| Interest Coverage | -419.58x | 1015.59x | - | - |
| Total Equity | -578.18K | 150.28K | 1.01M | 1.51M |
| Equity Growth % | - | 1.26% | 5.74% | 0.49% |
| Book Value per Share | -0.02 | 0.01 | 0.04 | 0.06 |
| Total Shareholders' Equity | -578.18K | 150.28K | 1.01M | 1.51M |
| Common Stock | 500 | 500 | 500 | 500 |
| Retained Earnings | -1.12M | -926.85K | -105.23K | 271.79K |
| Treasury Stock | 0 | 0 | 0 | 0 |
| Accumulated OCI | -48.83K | -45.82K | -43.51K | 72.59K |
| Minority Interest | 0 | 0 | 0 | 0 |
| Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | |
|---|---|---|---|---|
| Cash from Operations | -497.86K | 1.44M | 126.54K | 960.47K |
| Operating CF Margin % | -0.53% | 0.75% | 0.05% | 0.4% |
| Operating CF Growth % | - | 3.9% | -0.91% | 6.59% |
| Net Income | -484.96K | 191.3K | 852.04K | 478.56K |
| Depreciation & Amortization | 39.01K | 30.49K | 20.06K | 22.69K |
| Stock-Based Compensation | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | -1.29K | -33.74K | -21.46K |
| Other Non-Cash Items | 1.66K | 48.04K | 199.24K | 226.28K |
| Working Capital Changes | -53.57K | 1.17M | -911.07K | 254.41K |
| Change in Receivables | -46.67K | -143.85K | -603.5K | -135.6K |
| Change in Inventory | -19.23K | 193.58K | -2.82K | 10.47K |
| Change in Payables | 44.83K | 56.81K | 69.43K | -176.13K |
| Cash from Investing | -12.91K | -1.55M | 1.02M | -508.14K |
| Capital Expenditures | -12.91K | -11.89K | -22.68K | -85.57K |
| CapEx % of Revenue | 0.01% | 0.01% | 0.01% | 0.04% |
| Acquisitions | - | - | - | - |
| Investments | - | - | - | - |
| Other Investing | 0 | -1.54M | 1.05M | -422.57K |
| Cash from Financing | 498.63K | 669.65K | -676.92K | -957.39K |
| Debt Issued (Net) | - | - | - | - |
| Equity Issued (Net) | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - |
| Other Financing | 0 | 0 | 0 | -888.75K |
| Net Change in Cash | - | - | - | - |
| Free Cash Flow | -510.76K | 1.43M | 103.86K | 874.9K |
| FCF Margin % | -0.55% | 0.75% | 0.04% | 0.37% |
| FCF Growth % | - | 3.8% | -0.93% | 7.42% |
| FCF per Share | -0.02 | 0.05 | 0.00 | 0.03 |
| FCF Conversion (FCF/Net Income) | 1.03x | 7.54x | 0.15x | 2.01x |
| Interest Paid | 1.19K | 194 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 |
| Metric | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Return on Equity (ROE) | - | 127.3% | 146.56% | 38% |
| Return on Invested Capital (ROIC) | - | - | 8595.43% | 114.57% |
| Gross Margin | 66.58% | 73.47% | 87.35% | 91.8% |
| Net Margin | -52.09% | 9.97% | 34.65% | 20.09% |
| Debt / Equity | - | 0.17x | 0.03x | 0.05x |
| Interest Coverage | -419.58x | 1015.59x | - | - |
| FCF Conversion | 1.03x | 7.54x | 0.15x | 2.01x |
| Revenue Growth | - | 106.16% | 28.12% | -3.14% |
Park Ha Biological Technology Co., Ltd. Ordinary Shares (BYAH) has a price-to-earnings (P/E) ratio of 8.6x. This may indicate the stock is undervalued or faces growth challenges.
Park Ha Biological Technology Co., Ltd. Ordinary Shares (BYAH) reported $2.4M in revenue for fiscal year 2024. This represents a 156% increase from $0.9M in 2021.
Park Ha Biological Technology Co., Ltd. Ordinary Shares (BYAH) saw revenue decline by 3.1% over the past year.
Yes, Park Ha Biological Technology Co., Ltd. Ordinary Shares (BYAH) is profitable, generating $0.5M in net income for fiscal year 2024 (20.1% net margin).
Park Ha Biological Technology Co., Ltd. Ordinary Shares (BYAH) has a return on equity (ROE) of 38.0%. This is excellent, indicating efficient use of shareholder capital.
Park Ha Biological Technology Co., Ltd. Ordinary Shares (BYAH) generated $0.9M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.